These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
716 related articles for article (PubMed ID: 31779709)
1. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709 [TBL] [Abstract][Full Text] [Related]
2. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735 [TBL] [Abstract][Full Text] [Related]
3. Human platelet lysate enhances in vivo activity of CAR-Vδ2 T cells by reducing cellular senescence and apoptosis. Mo F; Tsai CT; Zheng R; Cheng C; Heslop HE; Brenner MK; Mamonkin M; Watanabe N Cytotherapy; 2024 Aug; 26(8):858-868. PubMed ID: 38506769 [TBL] [Abstract][Full Text] [Related]
4. Human Platelet Lysate Media Supplement Supports Lentiviral Transduction and Expansion of Human T Lymphocytes While Maintaining Memory Phenotype. Canestrari E; Steidinger HR; McSwain B; Charlebois SJ; Dann CT J Immunol Res; 2019; 2019():3616120. PubMed ID: 31565660 [TBL] [Abstract][Full Text] [Related]
5. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641 [No Abstract] [Full Text] [Related]
6. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678 [TBL] [Abstract][Full Text] [Related]
7. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo. Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967 [TBL] [Abstract][Full Text] [Related]
8. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Gargett T; Truong N; Ebert LM; Yu W; Brown MP Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603 [TBL] [Abstract][Full Text] [Related]
9. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204 [TBL] [Abstract][Full Text] [Related]
10. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655 [TBL] [Abstract][Full Text] [Related]
11. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926 [TBL] [Abstract][Full Text] [Related]
13. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710 [TBL] [Abstract][Full Text] [Related]
14. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314 [TBL] [Abstract][Full Text] [Related]
15. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function. Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139 [TBL] [Abstract][Full Text] [Related]
16. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199 [TBL] [Abstract][Full Text] [Related]
17. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells. Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119 [TBL] [Abstract][Full Text] [Related]
18. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720 [TBL] [Abstract][Full Text] [Related]
19. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589 [TBL] [Abstract][Full Text] [Related]
20. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]